Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(2.83)
# 1,635
Out of 5,241 analysts
110
Total ratings
51.52%
Success rate
5.86%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Neutral | n/a | $0.34 | - | 2 | Mar 23, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $3.61 | +177.01% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $109.14 | +110.74% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.73 | +131.21% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $6.28 | +75.16% | 2 | Oct 30, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $568.58 | -7.66% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $51.81 | +73.71% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $436.95 | +9.85% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $57.00 | -3.51% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $129.58 | -38.26% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $12.25 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $698.25 | +45.36% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $326.31 | +24.12% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $286.98 | -23.34% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $15.28 | -34.55% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $3.09 | +110.36% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $48.41 | +48.73% | 1 | Apr 13, 2023 |
Gossamer Bio
Mar 23, 2026
Downgrades: Neutral
Price Target: n/a
Current: $0.34
Upside: -
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $3.61
Upside: +177.01%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $109.14
Upside: +110.74%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.73
Upside: +131.21%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $6.28
Upside: +75.16%
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $568.58
Upside: -7.66%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $51.81
Upside: +73.71%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $436.95
Upside: +9.85%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $57.00
Upside: -3.51%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $129.58
Upside: -38.26%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $12.25
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $698.25
Upside: +45.36%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $326.31
Upside: +24.12%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $286.98
Upside: -23.34%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $15.28
Upside: -34.55%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $3.09
Upside: +110.36%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $48.41
Upside: +48.73%